MD, Chief Physician, Professor, Doctoral Supervisor, Deputy Director of the Department of Head and Neck Surgery. After obtaining his Doctor of Medicine in Oncology from Beijing Medical University in 1993, he joined the Department of Head and Neck Surgery of this hospital. He completed his post‑doctoral medical research in the United Kingdom in 1998 and resumed his practice in head and neck surgery at this hospital upon returning to China. He has visited world‑renowned cancer centers in the United States, including The University of Texas MD Anderson Cancer Center and Memorial Sloan‑Kettering Cancer Center, for clinical and academic exchanges, and maintains sound collaborative ties with them. He has successively served as Resident Physician, Attending Physician, Associate Chief Physician, Associate Professor, Chief Physician and Professor.

Through years of clinical practice in head and neck surgery, he has developed and summarized the large single‑wall arc incision and multi‑function preservation technique for cervical lymph node dissection of the head and neck. This approach achieves thorough intraoperative dissection, satisfactory functional preservation, inconspicuous post‑operative incisions with favorable cosmetic outcomes, and marked improvement in patients’ quality of life. He has performed minimally invasive and precise surgical procedures for over tens of thousands of patients with thyroid tumors, and pioneered a minimally invasive low‑cervical small‑arc incision. This surgical modality ensures standardized tumor resection and complete dissection of central‑compartment lymph nodes, featuring a low, small and well‑hidden incision. With cosmetic suture techniques, it produces minimal scars and excellent cosmetic effects, winning wide acclaim from patients. He has also explored novel comprehensive therapeutic regimens for advanced thyroid cancer with favorable clinical outcomes. Meanwhile, he is committed to the comprehensive treatment and research of other common head‑neck tumors, such as salivary gland tumors (parotid and submandibular gland tumors), oral tumors, laryngeal tumors, hypopharyngeal tumors and maxillary sinus tumors, and has achieved satisfactory clinical results.